Research programme: NR2F6 receptor modulators - Regen BioPharma

Drug Profile

Research programme: NR2F6 receptor modulators - Regen BioPharma

Alternative Names: RG NA01; RG NA02; RG NI01; RG NI02

Latest Information Update: 09 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regen BioPharma
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Orphan nuclear receptor agonists; Orphan nuclear receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 02 Mar 2017 Regen BioPharma licenses CheckPoint Immunology an exclusive worldwide license to develop and commercialise its NR2F6 technology for human therapeutic use
  • 21 Sep 2016 Preclinical trials in Autoimmune disorders in USA (PO)
  • 14 Jun 2016 Early research in Autoimmune disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top